Skip to Main Content

Paper Details

Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models.
J Clin Invest
47
2020
ALK1, ALK2, AVMs, Akt, BMP9, BMP9/, BMP9/10, BMP9/10ib, ECs, ENG, HHT, Hereditary hemorrhagic telangiectasia, PI3K, Sirolimus, Smad1/5/8, VEGFR2, anemia, arteriovenous malformations, endothelial, endothelial cells, gastrointestinal bleeding, genetic bleeding disorder, hereditary hemorrhagic telangiectasia, mTOR, mice, mouse, nintedanib, patient, patients, primary ECs, receptor tyrosine kinase, retinal AVMs, retinal bleeding, sirolimus, tyrosine, vascular pathology
Author NameAffiliation
Aya Nomura-KitabayashiLitwin-Zucker Center for Alzheimer's Disease and Memory Disorders and.
Fabien CampagneThe HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine and.
Fabien CampagneWeill Cornell Medical College
Fabien CampagneThe HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine and.
Fabien CampagneWeill Cornell Medical College
  • 1 - 5

Datasets

Release 1.2